Abstract
Raltegravir (RAL) is the first licensed antiretroviral integrase inhibitor that may be used both for treatment-naïve human immunodeficiency virus type 1 (HIV-1) patients and for salvage therapy. The Brazilian public free access programme limits its use for salvage therapy, with scarce information regarding RAL resistance from patients failing a RAL-containing salvage regimen. This study evaluated RAL resistance mutations detected by population sequencing in 69 HIV-infected patients with advanced disease failing a RAL-containing regimen in a real-world setting. RAL resistance mutations were identified in 47/69 patients (68%). The most common salvage regimen, used by 56/69 patients (81%), included lamivudine, tenofovir, darunavir/ritonavir and RAL. At failure, major RAL resistance mutations included Q148H/R/K (21/47; 45%), N155H (14/47; 30%), Y143R/H/C (3/47; 6%) and E92Q (1/47; 2%). Most samples with Q148H/R/K also showed G140S/A/C (21/47; 45%). RAL resistance was significantly associated with less than two active drugs in the optimised background therapy regimen at failure [39/39 (100%) vs. 9/17 (53%); P<0.001] and with a longer cumulative duration with detectable viraemia (viral load >50 copies/mL) (86 weeks vs. 32 weeks; P=0....Continue Reading
References
Oct 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·A S EspesethD J Hazuda
May 4, 2005·Memórias do Instituto Oswaldo Cruz·Rosangela RodriguesLuís Fernando de Macedo Brígido
Jul 16, 2008·Antiviral Research·Masanori KobayashiTamio Fujiwara
Jul 25, 2008·The New England Journal of Medicine·Roy T SteigbigelUNKNOWN BENCHMRK Study Teams
Aug 19, 2008·Journal of Virological Methods·Kristel Van LaethemAnne-Mieke Vandamme
Aug 4, 2009·Lancet·Jeffrey L LennoxUNKNOWN STARTMRK investigators
Dec 1, 2010·Antimicrobial Agents and Chemotherapy·Masanori KobayashiTamio Fujiwara
Feb 18, 2011·AIDS·Sébastien GallienDaniel R Kuritzkes
Jun 23, 2011·Infection and Drug Resistance·Jean L MbisaPatricia A Cane
May 9, 2012·Antiviral Research·Jaqueline Souza CavalcantiLuís Fernando de Macedo Brígido
Jul 4, 2012·Lancet·Paul E SaxUNKNOWN GS-US-236-0102 study team
Oct 20, 2012·Journal of Medical Virology·Caroline Pereira Bittencourt PassaesMariza Gonçalves Morgado
Jan 9, 2013·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·José Ernesto VidalAdrián Vladimir Hernández
Apr 9, 2013·International Journal of Antimicrobial Agents·Anne-Geneviève MarcelinUNKNOWN ANRS AC11 Resistance Group